Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using establish...
Gespeichert in:
| Veröffentlicht in: | Alzheimer's & dementia 2015-07, Vol.11 (7), p.865-884 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 884 |
|---|---|
| container_issue | 7 |
| container_start_page | 865 |
| container_title | Alzheimer's & dementia |
| container_volume | 11 |
| creator | Weiner, Michael W Veitch, Dallas P Aisen, Paul S Beckett, Laurel A Cairns, Nigel J Cedarbaum, Jesse Donohue, Michael C Green, Robert C Harvey, Danielle Jack, Clifford R Jagust, William Morris, John C Petersen, Ronald C Saykin, Andrew J Shaw, Leslie Thompson, Paul M Toga, Arthur W Trojanowski, John Q |
| description | Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials. |
| doi_str_mv | 10.1016/j.jalz.2015.04.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4659407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1552526015001715</els_id><sourcerecordid>1698022079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6345-6b3c2ad3f98e8b1f308ee961025b813a02b8efe180ea64cc3def6b622f4bf96f3</originalsourceid><addsrcrecordid>eNqNUsGO0zAQjRCIXRZ-gAPKDQ40jB3bTSS0UrUsS1cVHIALF8txxq1DEnftpKvu1-PQpQIOiIvHst-89zRvkuQ5gYwAEW-arFHtXUaB8AxYBsAfJKeEczrjdF4-PN4FnCRPQmgAGBSEP05OqCAlyymcJlfLbqv0kDqTDhtMF-3dBm2H_mVI39mAKmD6EUfvbKfWtl-ny94OVg12h69TGgnTwcVK2NPkkVFtwGf39Sz5-v7yy8WH2erT1fJisZppkTM-E1WuqapzUxZYVMTkUCCWggDlVUFyBbQq0CApAJVgWuc1GlEJSg2rTClMfpacH3i3Y9VhrbEfvGrl1keDfi-dsvLPn95u5NrtJBO8ZDCPBK_uCby7GTEMsrNBY9uqHt0YJBFlAZTCvIxQeoBq70LwaI4yBOSUgGzklICcEpDAZEwgNr343eCx5dfII2BxANzaFvf_QSkXq2_X1_GY3mKEP0XeHjgwjnpn0cugLfYaa-tRD7J29t8ez_9q163trVbtd9xjaNzo-xiiJDJQCfLztEfTGkV5IHPC8x9TU78K</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1698022079</pqid></control><display><type>article</type><title>Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Weiner, Michael W ; Veitch, Dallas P ; Aisen, Paul S ; Beckett, Laurel A ; Cairns, Nigel J ; Cedarbaum, Jesse ; Donohue, Michael C ; Green, Robert C ; Harvey, Danielle ; Jack, Clifford R ; Jagust, William ; Morris, John C ; Petersen, Ronald C ; Saykin, Andrew J ; Shaw, Leslie ; Thompson, Paul M ; Toga, Arthur W ; Trojanowski, John Q</creator><creatorcontrib>Weiner, Michael W ; Veitch, Dallas P ; Aisen, Paul S ; Beckett, Laurel A ; Cairns, Nigel J ; Cedarbaum, Jesse ; Donohue, Michael C ; Green, Robert C ; Harvey, Danielle ; Jack, Clifford R ; Jagust, William ; Morris, John C ; Petersen, Ronald C ; Saykin, Andrew J ; Shaw, Leslie ; Thompson, Paul M ; Toga, Arthur W ; Trojanowski, John Q ; Alzheimer's Disease Neuroimaging Initiative</creatorcontrib><description>Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1016/j.jalz.2015.04.005</identifier><identifier>PMID: 26194320</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AD biomarker signature ; Alzheimer Disease - diagnosis ; Alzheimer Disease - therapy ; Alzheimer's disease ; Amyloid phenotyping ; Biomarkers ; Clinical trial biomarkers ; Clinical Trials as Topic ; Data-sharing ; Databases, Bibliographic - statistics & numerical data ; Disease Progression ; Humans ; Longitudinal Studies ; Neuroimaging - methods ; Neurology ; Tau imaging ; Worldwide ADNI</subject><ispartof>Alzheimer's & dementia, 2015-07, Vol.11 (7), p.865-884</ispartof><rights>The Alzheimer's Association</rights><rights>2015 The Alzheimer's Association</rights><rights>Copyright © 2015 The Alzheimer's Association. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6345-6b3c2ad3f98e8b1f308ee961025b813a02b8efe180ea64cc3def6b622f4bf96f3</citedby><cites>FETCH-LOGICAL-c6345-6b3c2ad3f98e8b1f308ee961025b813a02b8efe180ea64cc3def6b622f4bf96f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2Fj.jalz.2015.04.005$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1016%2Fj.jalz.2015.04.005$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26194320$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weiner, Michael W</creatorcontrib><creatorcontrib>Veitch, Dallas P</creatorcontrib><creatorcontrib>Aisen, Paul S</creatorcontrib><creatorcontrib>Beckett, Laurel A</creatorcontrib><creatorcontrib>Cairns, Nigel J</creatorcontrib><creatorcontrib>Cedarbaum, Jesse</creatorcontrib><creatorcontrib>Donohue, Michael C</creatorcontrib><creatorcontrib>Green, Robert C</creatorcontrib><creatorcontrib>Harvey, Danielle</creatorcontrib><creatorcontrib>Jack, Clifford R</creatorcontrib><creatorcontrib>Jagust, William</creatorcontrib><creatorcontrib>Morris, John C</creatorcontrib><creatorcontrib>Petersen, Ronald C</creatorcontrib><creatorcontrib>Saykin, Andrew J</creatorcontrib><creatorcontrib>Shaw, Leslie</creatorcontrib><creatorcontrib>Thompson, Paul M</creatorcontrib><creatorcontrib>Toga, Arthur W</creatorcontrib><creatorcontrib>Trojanowski, John Q</creatorcontrib><creatorcontrib>Alzheimer's Disease Neuroimaging Initiative</creatorcontrib><title>Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014</title><title>Alzheimer's & dementia</title><addtitle>Alzheimers Dement</addtitle><description>Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.</description><subject>AD biomarker signature</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - therapy</subject><subject>Alzheimer's disease</subject><subject>Amyloid phenotyping</subject><subject>Biomarkers</subject><subject>Clinical trial biomarkers</subject><subject>Clinical Trials as Topic</subject><subject>Data-sharing</subject><subject>Databases, Bibliographic - statistics & numerical data</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Neuroimaging - methods</subject><subject>Neurology</subject><subject>Tau imaging</subject><subject>Worldwide ADNI</subject><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUsGO0zAQjRCIXRZ-gAPKDQ40jB3bTSS0UrUsS1cVHIALF8txxq1DEnftpKvu1-PQpQIOiIvHst-89zRvkuQ5gYwAEW-arFHtXUaB8AxYBsAfJKeEczrjdF4-PN4FnCRPQmgAGBSEP05OqCAlyymcJlfLbqv0kDqTDhtMF-3dBm2H_mVI39mAKmD6EUfvbKfWtl-ny94OVg12h69TGgnTwcVK2NPkkVFtwGf39Sz5-v7yy8WH2erT1fJisZppkTM-E1WuqapzUxZYVMTkUCCWggDlVUFyBbQq0CApAJVgWuc1GlEJSg2rTClMfpacH3i3Y9VhrbEfvGrl1keDfi-dsvLPn95u5NrtJBO8ZDCPBK_uCby7GTEMsrNBY9uqHt0YJBFlAZTCvIxQeoBq70LwaI4yBOSUgGzklICcEpDAZEwgNr343eCx5dfII2BxANzaFvf_QSkXq2_X1_GY3mKEP0XeHjgwjnpn0cugLfYaa-tRD7J29t8ez_9q163trVbtd9xjaNzo-xiiJDJQCfLztEfTGkV5IHPC8x9TU78K</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Weiner, Michael W</creator><creator>Veitch, Dallas P</creator><creator>Aisen, Paul S</creator><creator>Beckett, Laurel A</creator><creator>Cairns, Nigel J</creator><creator>Cedarbaum, Jesse</creator><creator>Donohue, Michael C</creator><creator>Green, Robert C</creator><creator>Harvey, Danielle</creator><creator>Jack, Clifford R</creator><creator>Jagust, William</creator><creator>Morris, John C</creator><creator>Petersen, Ronald C</creator><creator>Saykin, Andrew J</creator><creator>Shaw, Leslie</creator><creator>Thompson, Paul M</creator><creator>Toga, Arthur W</creator><creator>Trojanowski, John Q</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201507</creationdate><title>Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014</title><author>Weiner, Michael W ; Veitch, Dallas P ; Aisen, Paul S ; Beckett, Laurel A ; Cairns, Nigel J ; Cedarbaum, Jesse ; Donohue, Michael C ; Green, Robert C ; Harvey, Danielle ; Jack, Clifford R ; Jagust, William ; Morris, John C ; Petersen, Ronald C ; Saykin, Andrew J ; Shaw, Leslie ; Thompson, Paul M ; Toga, Arthur W ; Trojanowski, John Q</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6345-6b3c2ad3f98e8b1f308ee961025b813a02b8efe180ea64cc3def6b622f4bf96f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>AD biomarker signature</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - therapy</topic><topic>Alzheimer's disease</topic><topic>Amyloid phenotyping</topic><topic>Biomarkers</topic><topic>Clinical trial biomarkers</topic><topic>Clinical Trials as Topic</topic><topic>Data-sharing</topic><topic>Databases, Bibliographic - statistics & numerical data</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Neuroimaging - methods</topic><topic>Neurology</topic><topic>Tau imaging</topic><topic>Worldwide ADNI</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weiner, Michael W</creatorcontrib><creatorcontrib>Veitch, Dallas P</creatorcontrib><creatorcontrib>Aisen, Paul S</creatorcontrib><creatorcontrib>Beckett, Laurel A</creatorcontrib><creatorcontrib>Cairns, Nigel J</creatorcontrib><creatorcontrib>Cedarbaum, Jesse</creatorcontrib><creatorcontrib>Donohue, Michael C</creatorcontrib><creatorcontrib>Green, Robert C</creatorcontrib><creatorcontrib>Harvey, Danielle</creatorcontrib><creatorcontrib>Jack, Clifford R</creatorcontrib><creatorcontrib>Jagust, William</creatorcontrib><creatorcontrib>Morris, John C</creatorcontrib><creatorcontrib>Petersen, Ronald C</creatorcontrib><creatorcontrib>Saykin, Andrew J</creatorcontrib><creatorcontrib>Shaw, Leslie</creatorcontrib><creatorcontrib>Thompson, Paul M</creatorcontrib><creatorcontrib>Toga, Arthur W</creatorcontrib><creatorcontrib>Trojanowski, John Q</creatorcontrib><creatorcontrib>Alzheimer's Disease Neuroimaging Initiative</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alzheimer's & dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weiner, Michael W</au><au>Veitch, Dallas P</au><au>Aisen, Paul S</au><au>Beckett, Laurel A</au><au>Cairns, Nigel J</au><au>Cedarbaum, Jesse</au><au>Donohue, Michael C</au><au>Green, Robert C</au><au>Harvey, Danielle</au><au>Jack, Clifford R</au><au>Jagust, William</au><au>Morris, John C</au><au>Petersen, Ronald C</au><au>Saykin, Andrew J</au><au>Shaw, Leslie</au><au>Thompson, Paul M</au><au>Toga, Arthur W</au><au>Trojanowski, John Q</au><aucorp>Alzheimer's Disease Neuroimaging Initiative</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014</atitle><jtitle>Alzheimer's & dementia</jtitle><addtitle>Alzheimers Dement</addtitle><date>2015-07</date><risdate>2015</risdate><volume>11</volume><issue>7</issue><spage>865</spage><epage>884</epage><pages>865-884</pages><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26194320</pmid><doi>10.1016/j.jalz.2015.04.005</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-5260 |
| ispartof | Alzheimer's & dementia, 2015-07, Vol.11 (7), p.865-884 |
| issn | 1552-5260 1552-5279 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4659407 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | AD biomarker signature Alzheimer Disease - diagnosis Alzheimer Disease - therapy Alzheimer's disease Amyloid phenotyping Biomarkers Clinical trial biomarkers Clinical Trials as Topic Data-sharing Databases, Bibliographic - statistics & numerical data Disease Progression Humans Longitudinal Studies Neuroimaging - methods Neurology Tau imaging Worldwide ADNI |
| title | Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A22%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%20Alzheimer's%20Disease%20Neuroimaging%20Initiative,%202004%20to%202014&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Weiner,%20Michael%20W&rft.aucorp=Alzheimer's%20Disease%20Neuroimaging%20Initiative&rft.date=2015-07&rft.volume=11&rft.issue=7&rft.spage=865&rft.epage=884&rft.pages=865-884&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1016/j.jalz.2015.04.005&rft_dat=%3Cproquest_pubme%3E1698022079%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1698022079&rft_id=info:pmid/26194320&rft_els_id=1_s2_0_S1552526015001715&rfr_iscdi=true |